With the swift introduction of approved immunotherapy approaches into the treatment landscape for many cancers, medical professionals across many care-delivery settings and specialties are tasked with the need to follow and ...
Nov 28, 2018
0
5
(HealthDay)—Adverse events for immune checkpoint inhibitors used to treat non-small cell lung cancer (NSCLC) may be more common in real-world settings than reported in the clinical trials that led to U.S. Food and Drug ...
Nov 20, 2018
0
0
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute ...
Nov 13, 2018
0
1
In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis ...
Nov 12, 2018
0
0
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory ...
Nov 8, 2018
0
0
Researchers have discovered that inhibiting CDK9, a DNA transcription regulator, reactivates genes that have been epigenetically silenced by cancer. Reactivation leads to restored tumor suppressor gene expression and enhanced ...
Oct 25, 2018
0
1
A high concentration of multi-strain probiotic helps to reduce mild to moderate episodes of chemotherapy-induced diarrhoea (CID) in cancer patients, according to results of a phase II/III study in India.
Oct 22, 2018
0
6
This year's award of the Nobel Prize for Physiology and Medicine to James P. Allison and Tasuku Honjo, for their work in the early 1990s on immune checkpoint proteins CTLA4 and PD1, is a fitting recognition of how their work ...
Oct 2, 2018
0
8
A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to the human papilloma virus (HPV) in a phase II clinical trial led by investigators ...
Sep 27, 2018
0
78
Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
Sep 13, 2018
0
20
